Short Interest in Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) Expands By 187.2%

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) saw a large increase in short interest in May. As of May 15th, there was short interest totaling 70,108 shares, an increase of 187.2% from the April 30th total of 24,410 shares. Currently, 0.6% of the company’s stock are sold short. Based on an average trading volume of 92,510 shares, the days-to-cover ratio is currently 0.8 days.

Lixte Biotechnology Price Performance

Shares of NASDAQ LIXT traded up $0.26 during trading hours on Friday, hitting $6.25. 40,306 shares of the company’s stock were exchanged, compared to its average volume of 102,991. Lixte Biotechnology has a 1-year low of $0.64 and a 1-year high of $6.50. The stock has a market capitalization of $77.39 million, a price-to-earnings ratio of -5.53 and a beta of 1.04. The company’s 50-day moving average price is $4.01 and its 200-day moving average price is $3.74.

Lixte Biotechnology (NASDAQ:LIXT) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($0.18) earnings per share for the quarter.

Hedge Funds Weigh In On Lixte Biotechnology

Large investors have recently made changes to their positions in the business. Axxcess Wealth Management LLC acquired a new position in Lixte Biotechnology in the 4th quarter valued at approximately $54,000. Geode Capital Management LLC raised its holdings in Lixte Biotechnology by 25.9% in the 4th quarter. Geode Capital Management LLC now owns 52,163 shares of the company’s stock valued at $205,000 after acquiring an additional 10,722 shares in the last quarter. Renaissance Technologies LLC raised its holdings in Lixte Biotechnology by 47.0% in the 4th quarter. Renaissance Technologies LLC now owns 107,500 shares of the company’s stock valued at $422,000 after acquiring an additional 34,350 shares in the last quarter. DRW Securities LLC raised its holdings in Lixte Biotechnology by 11.6% in the 4th quarter. DRW Securities LLC now owns 54,126 shares of the company’s stock valued at $213,000 after acquiring an additional 5,645 shares in the last quarter. Finally, Federation des caisses Desjardins du Quebec raised its holdings in Lixte Biotechnology by 83.6% in the 4th quarter. Federation des caisses Desjardins du Quebec now owns 93,380 shares of the company’s stock valued at $367,000 after acquiring an additional 42,530 shares in the last quarter. Institutional investors and hedge funds own 5.10% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings cut Lixte Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Lixte Biotechnology presently has an average rating of “Sell”.

About Lixte Biotechnology

Lixte Biotechnology Holdings, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for the treatment of cancer. The company’s research centers on selectively targeting key enzymes and pathways involved in DNA damage response and cell cycle regulation, with the goal of creating novel oncology drugs that improve patient outcomes with manageable safety profiles.

Lixte’s lead programs include selective inhibitors of cell cycle checkpoints and related targets, designed to potentiate the effects of standard-of-care chemotherapies and overcome resistance mechanisms.